Alembic Pharmaceuticals Limited — Investor Meet, 10-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharma's Q1 FY27 saw strong 26% revenue growth to INR 2,150 Cr, with EBITDA up 21% to INR 348 Cr (16% margin), and PAT rising 12% to INR 173 Cr. Growth was broad-based: India Branded +7% (Animal Health +24%), International Generics +37%, API +33%. US Generics surged 49%, partly due to new launches like Bosutinib. The company now projects US business growth at mid-to-high teens for FY27, improving overall FY27 outlook to mid-teens. Investments in US branded business (Pivya) and R&D continue, aiming for positive contribution from branded next fiscal. Management expressed confidence in future growth drivers despite a competitive environment.